Experimental setup: behavioral task, pharmacological manipulation and physiological responses.
A) Schematic representation of the behavioral task. Participants responded to the orientation (CW/CCW) of unilaterally presented Gabor stimuli that were embedded in noise (bilaterally presented). The likely location of the Gabor stimulus was cued (horizontal dash presented 0.33° left/right from fixation) with 80% validity before stimulus onset. B) Schematic overview of experimental sessions. Participants came to the lab on four occasions: one intake session and three experimental sessions. On the experimental sessions, participants received either placebo (PLC, data in orange), donepezil (DNP, 5mg, data in green) or atomoxetine (ATX, 40mg, data in blue). Drug order was counterbalanced across participants. C) Time schedule of experimental sessions. Participants received a pill on two moments in each session, one at the beginning of the session and a second pill two hours later. The first pill contained either placebo (PLC and ATX session) or donepezil (DNP session), the second pill was either a placebo (PLC and DNP session) or atomoxetine (ATX session). Behavioral testing started 4 hours after administration of the first pill. D) Baseline pupil diameter was measured before onset of the behavioral task. Participants fixated while the background luminance of the monitor was dimmed (for 15s) and then brightened (for 15s) to establish the pupil size in dark and bright circumstances. E) Pupil diameter during the dark (left) and bright (right) measurement windows for each drug condition separately. G-H) Effects of drug on heart rate (panel G) and mean arterial blood pressure (MAP; panel H, see Methods). Measurements were baseline-corrected to the first measurement taken right before ingestion of the first pill. I-J) Effects of drug on subjective ratings of alertness (panel I) and (panel J) calmness, derived from Visual Analogue Scale (VAS, see Methods). Abbr.: ATX: atomoxetine, PLC: placebo, DNP: donepezil